{"version":"1.0","provider_name":"Avalere Health Advisory","provider_url":"https:\/\/advisory.avalerehealth.com","title":"Part D Cost Pressures May Shape Future Alzheimer\u2019s Drug Management | Avalere Health Advisory","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"IOSumNF5GM\"><a href=\"https:\/\/advisory.avalerehealth.com\/insights\/part-d-cost-pressures-may-shape-future-alzheimers-drug-management\">Part D Cost Pressures May Shape Future Alzheimer\u2019s Drug Management<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/advisory.avalerehealth.com\/insights\/part-d-cost-pressures-may-shape-future-alzheimers-drug-management\/embed#?secret=IOSumNF5GM\" width=\"600\" height=\"338\" title=\"&#8220;Part D Cost Pressures May Shape Future Alzheimer\u2019s Drug Management&#8221; &#8212; Avalere Health Advisory\" data-secret=\"IOSumNF5GM\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","thumbnail_url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2020\/08\/3019-1-Kylie_Stengel_600x400-e1597870657980.jpg","thumbnail_width":600,"thumbnail_height":400,"description":"Several new disease-modifying Alzheimer\u2019s disease (AD) treatments have come to market in recent years as intravenous administrations, but as of May 2025, none of these have been launched in the pharmacy benefit. With growing prevalance of AD in the Medicare population, Part D liability (i.e., the portion of drug costs paid by plans) for new&hellip;"}